CORONA, Calif., June 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths. Dronabinol is the generic version of Solvay Pharmaceuticals' MARINOL(R) (dronabinol) CIII Capsules, indicated to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Dronabinol is also indicated to treat anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS). For the 12-months ending December 2007, Solvay reported MARINOL(R) sales of 105 million.
Under the terms of the supply agreement, Solvay Pharmaceuticals will supply the dronabinol capsules to the Company's subsidiary, Watson Pharma, which will market, sell and distribute the product in the United States. Solvay Pharmaceuticals will receive a share of the profits from Watson's sales of the generic product in the U.S. market. Further details on the agreement have not been disclosed.
Dronabinol should not be used by any patient who has a history of hypersensitivity to any cannabinoid or to sesame oil. Patients should not drive, operate machinery, or engage in hazardous activity until they establish that they can tolerate dronabinol and perform such tasks safely. Dronabinol should be used with caution in patients with a history of seizure disorder; patients with cardiac disorders; patients with a history of substance abuse (including alcohol abuse or dependence); patients with mania, depression, or schizophrenia (along with careful psychiatric monitoring); patients taking sedatives, hypnotics, or other psychoactive drugs; and in elderly patients, pregnant patients, nursing mothers, or pediatric patients. The most common side effects probably related to dronabinol are dizziness, feelings of exaggerated happiness, paranoid reaction, drowsiness, thinking abnormal, abdominal pain, nausea and vomiting.
For full prescribing information please visit http://www.watson.com.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.
Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.
MARINOL(R) is a registered trademark of Unimed Pharmaceuticals, LLC, a wholly-owned subsidiary of Solvay Pharmaceuticals, Inc.
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved